For almost all patients, IL-16 was detected at higher quantities in the tumor supernatant compared to the juxta-tumor, while the tumor-specific high FGF-2 levels were highly patient-dependent (Fig. 2D top panels). This evidence concerns the gene IL16 and neoplasm.